Dr. Reddy’s Laboratories has launched Tegoprazan, a novel patented molecule, in India for acid-related gastrointestinal diseases under the brand name PCAB®. This launch follows an exclusive partnership with HK inno.N Corporation. Tegoprazan, a next-generation potassium-competitive acid blocker, addresses a critical need in acid peptic disease management. It has already been approved in 21 countries and has completed Phase-III trials in the United States.
Tegoprazan Launch in India
Dr. Reddy’s Laboratories has announced the launch of its novel molecule, Tegoprazan, in India, indicated for acid-related gastrointestinal diseases. The drug will be marketed under the brand name PCAB®.
About Tegoprazan
Tegoprazan is a next-generation potassium-competitive acid blocker used to treat acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD), and Gastric Ulcer. It offers fast action and prolonged gastric pH control, benefiting APD management.
Impact on the Market
With approximately 38% of the Indian population affected by APD, Tegoprazan’s launch addresses a significant need for effective management strategies. Clinical trials have shown promising results, including 99% endoscopic healing in GERD patients within 8 weeks in a multinational trial across India, South Africa, and Russia.
Executive Commentary
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr. Reddy’s, stated that the launch reinforces the company’s commitment to innovation in gastrointestinal disease treatment. Dal-Won Kwak, Chief Executive Officer at HK inno.N Corporation, expressed honor in introducing Tegoprazan to the Indian market, hoping it will become a leading therapy in its class.
Global Presence
Tegoprazan has already been approved in 21 countries, including South Korea and China, and is currently under registration in several other countries. It has also successfully completed Phase-III trials in the United States, indicating a broad potential market reach.
Source: BSE
